ライフサイエンスコーパス: risk of

1 We determined the age- and sex-adjusted risk of death for each type of synucleinopathy, the median ti

2 here was no significant association between younger age and risk of definitive treatment or risk of biochemical recurrenc

3 lso investigated associations between male circumcision and risk of acquisition of HIV and sexually transmitted infection

4 readmission use of drugs with anti-inflammatory effects and risk of new-onset depression and anxiety among adult patients

5 ed abstract and full-text screenings, data extractions, and risk of bias (ROB) assessments.

6 tions between changes in dietary inflammatory potential and risk of colorectal cancer (CRC) in 87,042 postmenopausal wome

7 illion 95% crI) of these 9.5 million (69.3%) pregnancies at risk of infection (and 53.4% [16.3 million/30.6 million] of a

8 of follow-up (1982-2012), there was no association between risk of hearing loss and hair color (for black hair vs. red o

9 Patients with WDTC treated with RAI had an increased early risk of developing AML and CML but no other hematologic malig

10 ons to identify patients with infection who are at elevated risk of poor outcomes.

11 We identified low but escalating risk of severe M. chimaera infection associated with heater-c

12 used, especially among female patients, to help monitor for risk of worsening fibrosis during MTX therapy.

13 Weight loss combined with sarcopenia presented the greatest risk of mortality.

14 S diagnosis identifies patients with very severe AS at high risk of death.

15 ffective strategy for the management of individuals at high risk of melanoma.

16 nt solutions to benefit patients with breast cancer at high risk of recurrence.

17 proteins, is restricted to prophylaxis in neonates at high risk of severe RSV disease.

18 with diabetes mellitus and prediabetes and those with high risk of cardiovascular disease, stroke, heart failure, and at

19 duals with more diabetes genetic risk alleles have a higher risk of developing DR.

20 CI, 1.07-1.44) center volumes were associated with a higher risk of early pancreas graft failure at 3 months.

21 An increased risk of definite AST was associated with shorter than with lo

22 ets, and mutations in Sox4 are associated with an increased risk of developing type 2 diabetes.

23 Patients with psoriasis have an increased risk of myocardial infarction, and psoriasis is now recognize

24 parenteral NSAIDs, was associated with a further increased risk of AMI.

25 Air pollution is associated with the increased risk of metabolic syndrome.

26 There should be close monitoring, for the increased risk of neurocognitive events in the ongoing outcome studies

27 New onset AF was associated with increased risk of all outcomes.

28 -0.08 days; P < .001) but was not associated with increased risk of any of the other secondary outcomes.

29 GPI use was associated with increased risk of bleeding in both treatment arms.

30 ay 90 (HR = 2.56, P < .0001) were associated with increased risk of DCGF; however, later-onset dysfunction requiring IBx

31 The only factor associated with increased risk of IC within 6 months was Roux-en-Y hepaticojejunostomy

32 However, extraction was associated with lower risk of device infections at 5 years.

33 Based on risk of death and return on investment, high-risk groups of t

34 ion between younger age and risk of definitive treatment or risk of biochemical recurrence after delayed RP.

35 Polygenic risk of autism and ADHD is associated with number of children

36 to use with most patients; however, some GBCAs have a small risk of adverse effects, including nephrogenic systemic fibro

37 for >/=2 years was associated with an increased subsequent risk of iron deficiency.

38 Although the risk of HF remained elevated among those with cAVB in the chr

39 Based on multivariable analysis, the risk of primary nonadherence was 16 percentage points lower a

40 nts by 25% (P=0.037) during the initial trial phase and the risk of coronary heart disease death, cardiovascular death, a

41 Our objective was to assess the risk of posttransplant cancer in this patient group.

42 Among patients with cirrhosis, statin use decreased the risk of decompensation, mortality, and HCC in a dose-dependen

43 In a large prospective cohort study, we evaluated the risk of breast cancer in relation to indoor heating and cooki

44 claim that supplementation leads to a large increase in the risk of advanced AMD in some genotype subgroups.

45 Longstanding diabetes might increase the risk of acute rejections.

46 Two questions that presented the risk of AK as not progressing to cancer had the lowest propor

47 ndividuals with LDL-C >/=190 mg/dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major adv

48 Assessing liver health may be important for reducing the risk of future CHF events, particularly among HIV and hepatit

49 e benefits of the enhanced host catabolic activity with the risk of being eliminated by the cell's cytosolic immune defen

50 ymptoms, health status, and AF treatment, as well as 2-year risk of death, hospitalization, thromboembolic events, heart